A fully integrated, R&D-driven biotechnology company listed on the Hong Kong Stock Exchange (1672.HK). ... biotech entity) and Shaoxing ...
News
- 1 in 4 ABC patients treated with Novartis Kisqali remain progression-free beyond 4 years
- CellRight Technologies, LLC Announces Update and Senior Leadership Changes
CellRight announces Senior leadership changes, implementation of new commercial plan and cost reduction initiatives. SAN ANTONIO, TX / ACCESS ...
- Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at ...
... San Antonio. The interview highlights the growing body of preclinical ... astr<60 is a webinar series created by astr partners for biotech and finance ...
- Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at ...
Ralph DeFronzo, Professor of Medicine and Chief of the Diabetes Division at UT Health San Antonio. ... biotech and finance leaders seeking clear, ...
- Pfizer's Tukysa delays HER2 breast cancer progression as 1st-line maintenance therapy
... San Antonio Breast Cancer Symposium. Patients who received the Pfizer ... Fierce Biotech · Fierce Healthcare · Fierce Pharma. Our Events. Life ...